These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22831987)

  • 1. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
    Campbell NP; Kunnavakkam R; Leighl N; Vincent MD; Gandara DR; Koczywas M; Gitlitz BJ; Agamah E; Thomas SP; Stadler WM; Vokes EE; Kindler HL
    Lung Cancer; 2012 Oct; 78(1):76-80. PubMed ID: 22831987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS; Moon J; Wistuba II; Vogelzang NJ; Kalemkerian GP; Redman MW; Gandara DR; Kelly K
    J Thorac Oncol; 2017 Aug; 12(8):1299-1308. PubMed ID: 28599887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Bender D; Sill MW; Lankes HA; Reyes HD; Darus CJ; Delmore JE; Rotmensch J; Gray HJ; Mannel RS; Schilder JM; Hunter MI; McCourt CK; Samuelson MI; Leslie KK
    Gynecol Oncol; 2015 Sep; 138(3):507-12. PubMed ID: 26186911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
    J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
    J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
    Garland LL; Chansky K; Wozniak AJ; Tsao AS; Gadgeel SM; Verschraegen CF; Dasilva MA; Redman M; Gandara DR
    J Thorac Oncol; 2011 Nov; 6(11):1938-45. PubMed ID: 21964533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
    Sridhar SS; Mackenzie MJ; Hotte SJ; Mukherjee SD; Tannock IF; Murray N; Kollmannsberger C; Haider MA; Chen EX; Halford R; Wang L; Ivy SP; Moore MJ
    Invest New Drugs; 2013 Aug; 31(4):1008-15. PubMed ID: 23354849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
    Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
    Lee JM; Cimino-Mathews A; Peer CJ; Zimmer A; Lipkowitz S; Annunziata CM; Cao L; Harrell MI; Swisher EM; Houston N; Botesteanu DA; Taube JM; Thompson E; Ogurtsova A; Xu H; Nguyen J; Ho TW; Figg WD; Kohn EC
    J Clin Oncol; 2017 Jul; 35(19):2193-2202. PubMed ID: 28471727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
    Hubbard JM; Yin J; Schenk EL; Qin R; Reid JM; Strand C; Fiskum J; Menefee M; Lin G; Doyle LA; Ivy P; Erlichman C; Adjei A; Haluska P; Costello BA
    Invest New Drugs; 2022 Feb; 40(1):115-123. PubMed ID: 34515877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
    Jahan T; Gu L; Kratzke R; Dudek A; Otterson GA; Wang X; Green M; Vokes EE; Kindler HL
    Lung Cancer; 2012 Jun; 76(3):393-6. PubMed ID: 22197613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
    Hirte H; Lheureux S; Fleming GF; Sugimoto A; Morgan R; Biagi J; Wang L; McGill S; Ivy SP; Oza AM
    Gynecol Oncol; 2015 Jul; 138(1):55-61. PubMed ID: 25895616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
    Zhu AX; Ancukiewicz M; Supko JG; Sahani DV; Blaszkowsky LS; Meyerhardt JA; Abrams TA; McCleary NJ; Bhargava P; Muzikansky A; Sheehan S; Regan E; Vasudev E; Knowles M; Fuchs CS; Ryan DP; Jain RK; Duda DG
    Clin Cancer Res; 2013 Mar; 19(6):1557-66. PubMed ID: 23362324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
    Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
    Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
    Hyams DM; Chan A; de Oliveira C; Snyder R; Vinholes J; Audeh MW; Alencar VM; Lombard J; Mookerjee B; Xu J; Brown K; Klein P
    Invest New Drugs; 2013 Oct; 31(5):1345-54. PubMed ID: 23801303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
    Symonds RP; Gourley C; Davidson S; Carty K; McCartney E; Rai D; Banerjee S; Jackson D; Lord R; McCormack M; Hudson E; Reed N; Flubacher M; Jankowska P; Powell M; Dive C; West CML; Paul J
    Lancet Oncol; 2015 Nov; 16(15):1515-1524. PubMed ID: 26474517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).
    Cohen JW; Widemann BC; Derdak J; Dombi E; Goodwin A; Dompierre J; Onukwubiri U; Steinberg SM; O'Sullivan Coyne G; Kummar S; Chen AP; Glod J
    Pediatr Blood Cancer; 2019 Dec; 66(12):e27987. PubMed ID: 31502400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
    McWhirter E; Quirt I; Gajewski T; Pond G; Wang L; Hui J; Oza A
    Invest New Drugs; 2016 Apr; 34(2):231-5. PubMed ID: 26841902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
    Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
    J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
    Brown N; McBain C; Nash S; Hopkins K; Sanghera P; Saran F; Phillips M; Dungey F; Clifton-Hadley L; Wanek K; Krell D; Jeffries S; Khan I; Smith P; Mulholland P
    PLoS One; 2016; 11(5):e0156369. PubMed ID: 27232884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.